126 Participants Needed

Electronic Monitoring Device for HIV

(A-TEAM Trial)

MD
AS
Overseen ByAnita Shaperd, MPH
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: University of Illinois at Chicago
Must be taking: Antiretrovirals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The investigators propose using an electronic adherence device that is basically a pill container that can alert when it is not opened at a scheduled time. The investigators will use this device to alert the medication user at the time when medication is supposed to be taken if the device did not get opened and a pre-identified social support person or case manager when 2 or 7 consecutive days of nonadherence are detected, respectively. The investigators call our approach "A-Team" (Antiretroviral Therapy Electronic Adherence Monitoring). The aims of this application are to determine the acceptability and feasibility of real-time adherence monitoring in support persons and case managers of African American Men who have sex with Men and to test this approach for these men in a 6-month randomized controlled trial among 54 of these men living with HIV and measure ART adherence and viral suppression (the primary outcome).

Will I have to stop taking my current medications?

The trial does not specify whether you need to stop taking your current medications. However, since it involves monitoring adherence to your existing HIV medication, it seems likely that you will continue your current treatment.

What data supports the effectiveness of the A-TEAM treatment for HIV?

Research shows that using electronic monitoring devices can improve adherence to antiretroviral therapy, with one study noting an increase in adherence from 84% to 93% when real-time monitoring and follow-up were used. Additionally, technology-driven interventions, like electronic reminder devices, have been shown to significantly improve adherence in several studies, although more rigorous research is needed to confirm these findings.12345

Is the Electronic Monitoring Device for HIV safe for humans?

The research does not provide specific safety data for the Electronic Monitoring Device itself, but it does not report any safety concerns related to its use in monitoring medication adherence among HIV patients.26789

What makes the A-TEAM treatment unique for HIV?

The A-TEAM treatment is unique because it uses electronic monitoring devices to track when patients take their HIV medication, allowing for real-time interventions if doses are missed. This approach aims to improve adherence to antiretroviral therapy, which is crucial for controlling the virus and preventing progression to AIDS.3571011

Research Team

MD

Mark Dworkin, MD

Principal Investigator

University of Illinois Chicago

Eligibility Criteria

This trial is for African American men who have sex with men, over 18 years old, living with HIV and struggling with medication adherence. They must be on antiretroviral therapy (ART) for at least six months, own a cell phone, and have either a detectable viral load or self-reported poor adherence. A supportive case manager or person from their social circle also needs to participate.

Inclusion Criteria

I am over 18 years old.
I am over 18 years old and have self-reported as HIV positive.
I own a working cell phone.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the A-TEAM intervention with real-time electronic adherence monitoring for 6 months

6 months
Monthly check-ins (virtual or in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • A-TEAM
Trial OverviewThe 'A-Team' intervention uses an electronic pill container that alerts the user when it's time to take their medication and notifies a support person if doses are missed. The study will test its effectiveness in improving ART adherence and achieving viral suppression over six months in a randomized controlled trial.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: A-TEAMExperimental Treatment1 Intervention
This arm receives the A-TEAM approach where the men, their social support (if they have one), and their case manager participate. If the adherence device identifies non-opening of the device, the men are alerted by text or email the same day. If the device identifies non-opening of the device two days in a row, the social support (or case manager) is notified, and if 7 days of non-opening is detected, the case manager is notified.
Group II: ControlActive Control1 Intervention
The men are monitored with the adherence device but there is no intervention on their adherence - they otherwise experience routine care and they don't receive alerts if they the device detects non-openings.

A-TEAM is already approved in United States for the following indications:

🇺🇸
Approved in United States as A-Team for:
  • HIV treatment adherence support

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Illinois at Chicago

Lead Sponsor

Trials
653
Recruited
1,574,000+

Massachusetts General Hospital

Collaborator

Trials
3,066
Recruited
13,430,000+

Findings from Research

Technology-driven interventions, including mobile phones and internet-based approaches, have shown significant effectiveness in improving adherence to antiretroviral therapy (ART) among individuals living with HIV, based on a review of 13 studies conducted between 2013 and 2015.
These technology-enhanced strategies not only support ART adherence but also lead to better clinical outcomes, highlighting their potential as a low-cost solution to manage the increasing demand for HIV care.
Evidence for Technology Interventions to Promote ART Adherence in Adult Populations: a Review of the Literature 2012-2015.Amico, KR.[2022]
Switching from standard electronic adherence monitoring to real-time electronic adherence monitoring significantly improved antiretroviral therapy adherence among 112 participants, increasing from 84% to 93%.
This elevated adherence level was sustained for 6 months after the switch, indicating that real-time monitoring could be an effective strategy for enhancing treatment compliance.
Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring.Haberer, JE., Musinguzi, N., Tsai, AC., et al.[2022]
The review analyzed 15 studies on electronic reminder devices (ERDs) aimed at improving adherence to antiretroviral therapy (ART) among people living with HIV/AIDS, finding that while some studies reported improved adherence, the overall evidence was inconclusive due to methodological limitations.
Patient satisfaction with ERDs was generally positive, but the impact of these devices on virological and immunological outcomes was inconsistent, highlighting the need for more rigorous research to determine their effectiveness.
Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review.Wise, J., Operario, D.[2022]

References

Evidence for Technology Interventions to Promote ART Adherence in Adult Populations: a Review of the Literature 2012-2015. [2022]
Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. [2022]
Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. [2022]
Electronic medication monitoring-informed counseling to improve adherence to combination anti-retroviral therapy and virologic treatment outcomes: a meta-analysis. [2020]
Acceptability and Feasibility of Real-Time Antiretroviral Therapy Adherence Interventions in Rural Uganda: Mixed-Method Pilot Randomized Controlled Trial. [2023]
Returning of antiretroviral medication dispensed over a period of 8 months suggests non-adherence despite full adherence according to real time medication monitoring. [2021]
Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. [2006]
Cell Phone-Based and Adherence Device Technologies for HIV Care and Treatment in Resource-Limited Settings: Recent Advances. [2018]
HIV adherence strategies take a high-tech route. [2016]
Factors Affecting the Implementation of Electronic Antiretroviral Therapy Adherence Monitoring and Associated Interventions for Routine HIV Care in Uganda: Qualitative Study. [2021]
11.United Statespubmed.ncbi.nlm.nih.gov
Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. [2020]